Intraperitoneal Bevacizumab to Treat Symptomatic Ascites in Chemotherapy-Resistant, Epithelial Ovarian Cancer
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Gynecologic Oncology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
REZOLVE (ANZGOG-1101): A Phase 2 Trial of Intraperitoneal Bevacizumab to Treat Symptomatic Ascites in Patients With Chemotherapy-Resistant, Epithelial Ovarian Cancer
Gynecol. Oncol 2021 Feb 23;[EPub Ahead of Print], KM Sjoquist, D Espinoza, L Mileshkin, S Ananda, C Shannon, S Yip, J Goh, D Bowtell, M Harrison, ML FriedlanderFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.